On August 18, 2021, Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90 million Series B financing. The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures, and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures. Wilson Sonsini Goodrich & Rosati represented Vida Ventures in the transaction.

The financing will be used to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. Vigil is developing both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), an essential microglia sensor that mediates responses to environmental signals to maintain brain homeostasis.

The Wilson Sonsini team advising Vida Ventures includes:

Corporate
Jennifer Fang
Mark Solakian
Priyanka Nawathe
Andrew Thompson

Patents & Innovations
Vern Norviel
Lori Westin
Clark Lin
Dustin Luettgen
Joe Lesniewski

Please see Vigil Neuroscience’s press release for more information.